



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 59880

Title: Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy

Reviewer's code: 03093768

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor, Chief Doctor, Doctor, Surgeon, Surgical Oncologist

Reviewer's Country/Territory: China

Author's Country/Territory: South Korea

Manuscript submission date: 2021-02-24

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-02-27 05:18

Reviewer performed review: 2021-03-05 13:17

Review time: 6 Days and 7 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

It should be said that research on NLR and CA19-9 in the field of advanced pancreatic cancer is not uncommon. As a retrospective study, this article is a certain supplement to other similar studies. The article summarizes and analyzes the case characteristics of the author's medical center. There are some questions that need to be answered. 1. The exact definition of advanced pancreatic cancer needs to be explained. Is the locally advanced cancer truly advanced? Is there any literature support? Of course, I have also seen many literatures that local advanced pancreatic cancer was included as advanced pancreatic cancer for statistical analysis. 2. First-line chemotherapy is therapeutic chemotherapy for pancreatic cancer, not first-line palliative chemotherapy. The manuscript mentioned palliative chemotherapy in the part of method (line 40), why? 3. There are several modes of first-line chemotherapy. In this article, the first-line chemotherapy based on gemcitabine and other chemotherapy programs are not described in detail. It is recommended that the chemotherapy be clearly stated. 4. The article mentioned that chemotherapy was performed at least one cycle, but the evaluations were completed after two cycles of chemotherapy. Why? 5. The time for obtaining blood test specimens is too vague, and it is recommended to specify clearly. 6. Although most patients had an overall survival time of less than 12 months, but some patients had a survival time more than 3 years (according to the data in the article), was it reasonable to use a 1-year survival period as an ROC curve? Explanation is needed. 7. Some flaws about data, icons, grouping and others are annotated in the text, please read it.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 59880

Title: Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy

Reviewer's code: 03093768

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor, Chief Doctor, Doctor, Surgeon, Surgical Oncologist

Reviewer's Country/Territory: China

Author's Country/Territory: South Korea

Manuscript submission date: 2021-02-24

Reviewer chosen by: Chen-Chen Gao

Reviewer accepted review: 2021-05-06 13:22

Reviewer performed review: 2021-05-06 15:11

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

1. In the section of “patients”, the chemotherapy is still called first-line palliative chemotherapy 2. No “table 4” was found in the manuscript. 3. In “table 1”, the number of patients “721” should be “271”. This kind of mistake is ridiculous. 4. The groups were labeled as “A, B, C” in the text but “a, b, c” in the figures. It should be consistent.